Once-daily Xibrom could be with us soon

Results of a Phase III trial of the once-daily formulation of Xibrom (ISTA Pharmaceuticals) has found it to be both safe and efficacious.

Results of a Phase III trial of the once-daily formulation of Xibrom (ISTA Pharmaceuticals) for the treatment of ocular inflammation and pain associated with cataract surgery, has found it to be both safe and efficacious.

The multicentre study evaluated the once-daily formulation versus placebo in more than 500 patients who had undergone cataract surgery. Preliminary analyses of the results have found the safety profile to be consistent with the currently marketed twice-daily formulation of Xibrom.

ISTA plans to file a supplemental New Drug Application (sNDA) with the FDA during the second half of 2007.

Related Videos
Disrupting the glaucoma treatment paradigm with novel femtosecond laser from ViaLase
2-year data in contralateral eye evaluation gives edge to iStent inject over Hydrus stent
Should endocyclophotocoagulation be considered part of MIGS? Mr Ratnarajan delves in
Investigating the effects of canaloplasty on corneal epithelium
Related Content
© 2023 MJH Life Sciences

All rights reserved.